logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

InflaRx N.V.

IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a moā€¦ read more

Healthcare

Biotechnology

5 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.91

Price

+5.74%

$0.05

$0.86

Previous Close

$0.88

Open

Premium

52w Discount
Market Cap

$61.252m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$129.750k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$44.721m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.76

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$70.466m

$87m

Assets

$16.534m

Liabilities

$702.630k

Debt
Debt to Assets

0.8%

-

Debt to EBITDA
Free Cash Flow

-$47.745m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in EUR.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.